Ognomy Sleep raises $20M to expand virtual sleep apnea care

Ognomy Sleep closed a $20 million Series A led by Catalyst Investors to scale its AI-enabled, virtual sleep medicine platform across all 50 states. The Buffalo-based company says the funding will help expand care delivery, wearable integrations and partnerships as it pushes deeper into cardiometabolic health.

Why it matters: - Ognomy Sleep is trying to widen access to sleep apnea diagnosis and treatment, a care gap the company links to a global population of more than one billion people. - The funding gives the company more runway to expand AI-enabled care delivery, which could improve speed, scalability and follow-up for patients. - Ognomy is building one of the country’s largest virtual sleep medicine networks, a position that could matter as sleep health becomes more tied to chronic disease management.

What happened: - Ognomy Sleep raised $20 million in a Series A round. - Catalyst Investors led the financing. - Blue Heron Capital participated in the round. - New and follow-on investors included Impellent Ventures, LaunchNY, Excell, Upstate Biotech Ventures, University at Buffalo and strategic partners that backed the company early. - The company said the capital will support its next phase of growth.

The details: - Ognomy Sleep operates a virtual sleep medicine platform focused on obstructive sleep apnea. - The platform covers referral, home sleep testing, diagnosis, treatment coordination and long-term adherence support. - Ognomy operates across all 50 states. - The company has completed more than 85,000 virtual visits nationwide. - Ognomy says it has market-leading therapy compliance and 80+ NPS ratings. - The company plans to expand its AI-enabled clinical platform and wearable integrations. - Ognomy also plans to deepen strategic partnerships across the healthcare ecosystem. - Founder and CEO Daniel Rifkin, a sleep medicine physician, said the company is investing in AI and automation while keeping the human connection central to care. - Ken Rosenfeld, chief operating officer, said the new backers validate the company’s clinician and staff work to build a scalable, outcomes-driven platform. - Catalyst Investors’ Kapil Desai is joining Ognomy’s board as part of the round.

Between the lines: - The raise signals investor confidence in virtual specialty care that combines clinical services with software and automation. - Ognomy is positioning sleep apnea treatment as part of a broader cardiometabolic care strategy, not just a standalone sleep market. - The company is also leaning on external validation, including national growth and award recognition, to reinforce its differentiation. - Ognomy was named the 2026 MedTech Breakthrough Award winner for Best Overall SleepTech Solution.

What's next: - Ognomy plans to use the new capital to accelerate growth and expand its platform capabilities. - The company is expected to continue building partnerships across healthcare and broadening its role in cardiometabolic health. - Ognomy will likely keep scaling its virtual-first sleep care model nationwide.

The bottom line: - Ognomy Sleep is using new funding to turn virtual sleep apnea care into a larger, AI-driven national platform.